Jehn U, De Bock R, Haanen C
Blut. 1984 May;48(5):255-61. doi: 10.1007/BF00320395.
In a multicenter analysis, the effect of low-dose cytosine arabinoside (Ara-C)(10 mg/ m2q 12 h subcutaneously for a minimum of 15 days) has been assessed in 13 patients with acute leukemia (10 myeloid-AML-, 3 lymphocytic-ALL-) and 7 patients with dysmyelopoietic syndromes (DMPS), conditions classified as refractory anemia with an excess of blasts ( RAEB ). Seven patients suffering from acute leukemia and 1 with DMPS in blastic transformation displayed a leukocytosis of more than 10 X 10(9)/1. Three out of 7 DMPS, 1 out of 10 AML achieved a complete remission, 1 out of 3 ALL-patients reached a partial remission twice. Seven patients showed a blast clearing in the bone marrow and peripheral blood, in another 7 instances examination of the bone marrow was not performed after therapy because of early death. The majority of patients were in their late phase of disease and refractory to conventional chemotherapy. Only 5 patients had no pretreatment at first presentation before low-dose Ara-C was initiated. At least for the DMPS-group, this therapeutic approach seems to be of some benefit.
在一项多中心分析中，对13例急性白血病患者（10例髓性白血病-急性髓系白血病，3例淋巴细胞性白血病-急性淋巴细胞白血病）和7例骨髓增生异常综合征（DMPS）患者（归类为原始细胞过多的难治性贫血，RAEB）评估了低剂量阿糖胞苷（Ara-C）（10 mg/m²，每12小时皮下注射，至少15天）的疗效。7例急性白血病患者和1例处于原始细胞转化期的DMPS患者出现白细胞增多，超过10×10⁹/L。7例DMPS患者中有3例、10例AML患者中有1例实现完全缓解，3例ALL患者中有1例两次达到部分缓解。7例患者骨髓和外周血中的原始细胞清除，另外7例在治疗后因早期死亡未进行骨髓检查。大多数患者处于疾病晚期，对传统化疗耐药。在开始低剂量Ara-C治疗时，只有5例患者首次就诊时未进行预处理。至少对于DMPS组，这种治疗方法似乎有一定益处。
